Skip to main content
Premium Trial:

Request an Annual Quote

Rising R&D, SG&A Costs Lead to Wider Q1 Net Loss for Rosetta Genomics

NEW YORK (GenomeWeb News) - Rosetta Genomics today said it generated no first-quarter sales, while its R&D spending climbed 30 percent, and its net loss increased 33 percent year over year.
Rosetta, which went public in February, said that R&D spending for the three months ended March 31, 2007, increased to $1.16 million from $886,000 in the year-ago period. R&D accounted for 52 percent of the company’s spending during the quarter.
The increase in R&D spending resulted primarily from increased costs related to the purchase of tissue samples and other research materials related to its Cancer of Unknown Primary (CUP) diagnostic program, “as well as an increase in costs relating to our intellectual property and costs associated with license fees,” the company said in a statement.
General and administrative expenses increased to $680,000 from $211,000 in the first quarter of 2006. Rosetta Genomics said these higher costs were due to legal and other fees associated with its initial public offering and operation as a public company.
The company’s quarterly net loss increased to $2 million from $1.5 million in the first quarter of 2006.
Rosetta Genomics said it had around $10.8 million in cash and cash equivalents as of March 31.
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.